ARCHIVES

Angiogenesis Inhibitor In Phase III Trials For Metastatic Colorectal Cancer

This article is from The Cancer Letter archive.

Vol. 26 No. 9 | September 26, 2003

Download PDF Visit The Full Archive

Related Articles

MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues

November 29, 2013

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

October 15, 2004

NCI Should Examine Alternative Therapies TA Report Says

September 28, 1990

In Brief: Advisory Committee On Women’s Health Chartered; CALGB Lists New Address

May 12, 1995

NCI Advisory Group Meetings for September

August 29, 1975

Tobacco Council Announces 11 New Grant Awards

January 24, 1975